DE69834808D1 - Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung - Google Patents

Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung

Info

Publication number
DE69834808D1
DE69834808D1 DE69834808T DE69834808T DE69834808D1 DE 69834808 D1 DE69834808 D1 DE 69834808D1 DE 69834808 T DE69834808 T DE 69834808T DE 69834808 T DE69834808 T DE 69834808T DE 69834808 D1 DE69834808 D1 DE 69834808D1
Authority
DE
Germany
Prior art keywords
carbohydrate
developed therefrom
vaccines developed
containing glycopeptide
glycopeptide antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69834808T
Other languages
English (en)
Other versions
DE69834808T2 (de
Inventor
Sylvie Bay
Daniele Cantacuzene
Claude Leclerc
Richard Lo-Man
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of DE69834808D1 publication Critical patent/DE69834808D1/de
Application granted granted Critical
Publication of DE69834808T2 publication Critical patent/DE69834808T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Carbon And Carbon Compounds (AREA)
DE69834808T 1997-03-27 1998-03-27 Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung Expired - Lifetime DE69834808T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4172697P 1997-03-27 1997-03-27
US41726P 1997-03-27
PCT/EP1998/001922 WO1998043677A1 (en) 1997-03-27 1998-03-27 Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof

Publications (2)

Publication Number Publication Date
DE69834808D1 true DE69834808D1 (de) 2006-07-20
DE69834808T2 DE69834808T2 (de) 2007-06-06

Family

ID=21918009

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834808T Expired - Lifetime DE69834808T2 (de) 1997-03-27 1998-03-27 Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung

Country Status (10)

Country Link
US (1) US7696326B2 (de)
EP (1) EP0969873B1 (de)
AT (1) ATE328611T1 (de)
AU (1) AU6832398A (de)
CA (1) CA2285018C (de)
DE (1) DE69834808T2 (de)
DK (1) DK0969873T3 (de)
ES (1) ES2265162T3 (de)
PT (1) PT969873E (de)
WO (1) WO1998043677A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
AU2992600A (en) * 1999-02-11 2000-08-29 Genzyme Corporation Antigenic peptide concatomers
EP1417965A1 (de) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin bindenden verbindungen, identifizierung und verwendungen davon
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
CN1747970A (zh) * 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
WO2005037190A2 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
JP5117191B2 (ja) * 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2007079448A2 (en) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
ES2366552T3 (es) 2006-01-13 2011-10-21 Institut Pasteur Síntesis enzimática a gran escala de glicoconjugados de mucina y sus aplicaciones en inmunología.
DK2052011T3 (da) * 2006-08-11 2020-12-07 Starpharma Pty Ltd Målrettet polylysin-dendrimer-terapeutisk stof
US9127130B2 (en) 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
JP5661735B2 (ja) 2009-04-01 2015-01-28 ユニバーシティ オブ マイアミ ワクチン組成物及びその使用方法
EP2500033A1 (de) 2011-03-17 2012-09-19 Institut Pasteur Verfahren zur Herstellung mehrfacher Antigen-Glycopeptid-Kohlenhydratkonjugate
US20160101187A1 (en) * 2012-10-02 2016-04-14 Novartis Ag Nonlinear saccharide conjugates
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
JP2019501964A (ja) * 2015-12-14 2019-01-24 ハン， スーＨＡＮ， Ｓｕ ポリペプチド化合物、並びにその調製方法及び適用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DK0532525T3 (da) * 1990-05-18 1995-12-04 Genentech Inc Nye protein-polykationkonjugater
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof

Also Published As

Publication number Publication date
WO1998043677A1 (en) 1998-10-08
ES2265162T3 (es) 2007-02-01
PT969873E (pt) 2006-09-29
CA2285018A1 (en) 1998-10-08
US7696326B2 (en) 2010-04-13
DK0969873T3 (da) 2006-10-09
ATE328611T1 (de) 2006-06-15
AU6832398A (en) 1998-10-22
EP0969873B1 (de) 2006-06-07
US20070098730A1 (en) 2007-05-03
DE69834808T2 (de) 2007-06-06
CA2285018C (en) 2011-01-04
EP0969873A1 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
ES2093778T3 (es) Nuevos anticuerpos y metodos para su uso.
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
WO1996029605A3 (en) Compounds and methods for the dectection of t. cruzi infection
AR007249A1 (es) Preparacion concentrada de anticuerpos
BR9809656A (pt) Composição imunopotencializante
AU8316701A (en) Anti-dual integrin antibodies, compositions, methods and uses
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
NO950881L (no) Nöytraliserende monoklonale menneske-antistoffer mot respiratorisk syncytialt virus
YU49370B (sh) Postupak za pripremanje vakcine protiv lajmske bolesti
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
ATE233102T1 (de) Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
SE9401460D0 (sv) Antigen/antibody specificity exhanger
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
PT856520E (pt) Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico
EP1354896A4 (de) Neuer monoklonaler antikörper
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
EP0453097A3 (de) Composition comprising at least two different antibodies or fragments thereof
ATE444081T1 (de) Proteine-abgabe durch polare epithelzellen schichte
NO168746C (no) Antistoff som er istand til aa binde histamin
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE69617255T2 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition